E. Ohman J or Asset Management AB Sells 81,208 Shares of Terns Pharmaceuticals, Inc. $TERN

E. Ohman J or Asset Management AB lessened its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 79.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 21,202 shares of the company’s stock after selling 81,208 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Terns Pharmaceuticals were worth $857,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TERN. GAMMA Investing LLC lifted its position in shares of Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after purchasing an additional 770 shares during the period. Polymer Capital Management US LLC bought a new position in Terns Pharmaceuticals during the third quarter worth $76,000. Engineers Gate Manager LP acquired a new position in Terns Pharmaceuticals in the second quarter valued at $41,000. Fox Run Management L.L.C. acquired a new position in Terns Pharmaceuticals in the third quarter valued at $87,000. Finally, Canada Pension Plan Investment Board bought a new stake in Terns Pharmaceuticals during the second quarter valued at $46,000. Institutional investors own 98.26% of the company’s stock.

Insider Activity

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 14,583 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the transaction, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the sale, the insider directly owned 50,365 shares of the company’s stock, valued at $1,942,578.05. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 170,409 shares of company stock valued at $6,563,769. 1.50% of the stock is currently owned by company insiders.

Terns Pharmaceuticals News Roundup

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to an all-cash acquisition at $53.00 per share, approved by both boards and structured as a tender offer with expected closing in Q2 2026 — the deal provides a clear near-term valuation floor and validates Terns’ lead asset, TERN-701, as strategically valuable to a large pharma buyer. Read More.
• Positive Sentiment: Major media and wire services emphasize the strategic fit (adding a CML allosteric BCR::ABL1 inhibitor) and Merck’s broader push to refill its oncology pipeline ahead of Keytruda’s patent cliff — reinforcing deal rationale for investors. Read More.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $53 price target (essentially aligned with the offer price), suggesting limited upside beyond the transaction price while the deal closes. Read More.
• Neutral Sentiment: Deal mechanics: transaction is a tender offer contingent on shareholder participation and customary closing conditions — market will watch vote/acceptance levels, regulatory review and timing rather than Terns’ standalone clinical milestones. Read More.
• Negative Sentiment: Multiple shareholder-law firms have launched investigations into whether Terns’ board obtained a fair price (Monteverde, Ademi, Halper Sadeh), which could lead to litigation, delay or pressure on deal terms — a risk for timing and transaction certainty. Read More. Read More. Read More.

Terns Pharmaceuticals Trading Up 5.7%

TERN opened at $52.86 on Thursday. The company has a fifty day moving average price of $40.63 and a two-hundred day moving average price of $28.57. Terns Pharmaceuticals, Inc. has a 1-year low of $1.87 and a 1-year high of $52.98. The company has a market cap of $5.48 billion, a P/E ratio of -51.32 and a beta of -0.31.

Wall Street Analyst Weigh In

TERN has been the subject of several research analyst reports. TD Cowen raised Terns Pharmaceuticals to a “strong-buy” rating in a research report on Friday, February 20th. Truist Financial upped their target price on Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. UBS Group raised Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th. Finally, Barclays boosted their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Terns Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $57.33.

Terns Pharmaceuticals Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.